IS IT TIME FOR MULTI-DRUG THERAPY WITH COMBINATION OF THERAPEUTIC NUCLEIC ACIDS?

Therapeutic nucleic acids (TNAs) are a new class of drugs that exhibit different properties and mechanisms of action from those of small molecules or biological drugs. Over twenty oligonucleotide drugs and several COVID-19 vaccines have received regulatory approval for clinical use. A characteristic...

Full description

Saved in:

Bibliographic Details
Published in:	ChemMedChem p. e202400493
Main Author:	Lesnikowski, Zbigniew Jan
Format:	Journal Article
Language:	English
Published:	Germany 26-10-2024
Subjects:	nucleic acid therapeutics antisense oligonucleotides, multidrug therapy combinations, drug carriers nanoparticles
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Therapeutic nucleic acids (TNAs) are a new class of drugs that exhibit different properties and mechanisms of action from those of small molecules or biological drugs. Over twenty oligonucleotide drugs and several COVID-19 vaccines have received regulatory approval for clinical use. A characteristic feature of these TNAs is that they are directed against one specific biological target and one specific RNA or DNA sequence. Consequently, TNAs currently used are administered as monotherapy. Due to the known advantages of multidrug therapy with low molecular weight drugs, it may be time to intensify work on such a treatment protocol, also in the case of TNAs.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1860-7179 1860-7187 1860-7187
DOI:	10.1002/cmdc.202400493